| Carbonic anhydrase inhibitor | |
|---|---|
| Drug class | |
 | |
| Class identifiers | |
| Use | Glaucoma |
| ATC code | S01EC |
| Biological target | Carbonic anhydrase |
| Clinical data | |
| Drugs.com | Drug Classes |
| External links | |
| MeSH | D002257 |
| Legal status | |
| In Wikidata | |
Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.[1][2][3]
- ^ Supuran CT, Scozzafava A, Conway J, eds. (2004). Carbonic anhydrase: its inhibitors and activators. Boca Raton: CRC Press. ISBN 978-0-415-30673-7.[page needed]
- ^ Supuran, Claudiu T; Scozzafava, Andrea (2000). "Carbonic anhydrase inhibitors and their therapeutic potential". Expert Opinion on Therapeutic Patents. 10 (5): 575–600. doi:10.1517/13543776.10.5.575. S2CID 86519198.
- ^ Supuran, Claudiu T.; Scozzafava, Andrea; Casini, Angela (2003). "Carbonic anhydrase inhibitors". Medicinal Research Reviews. 23 (2): 146–89. doi:10.1002/med.10025. PMID 12500287.